Search Results - "Tamminga, Wim J"

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers by Stangier, Joachim, Schmid, Jochen, Türck, Dietrich, Switek, Heinz, Verhagen, Aalt, Peeters, Pierre A. M., van Marle, Sjoerd P., Tamminga, Wim J., Sollie, Frans A. E., Jonkman, Jan H. G.

“…The study was conducted in healthy male volunteers to evaluate the absorption, metabolic pattern, and mode of elimination of telmisartan, a nonpeptide…”
Get full text

The impact of Cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice by Mulder, Hans, Herder, Anita, Wilmink, Frederik W., Tamminga, Wim J., Belitser, Svetlana V., Egberts, Antoine C. G.

“…Purpose This retrospective follow‐up study investigates whether cytochrome P450‐2D6 (CYP2D6) genotype explains variability in plasma concentrations of…”
Get full text

The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study by Mulder, Hans, Wilmink, Frederik W, Beumer, Tim L, Tamminga, Wim J, Jedema, Jaap N, Egberts, Antoine C G

Get full text

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study by TAMMINGA, Wim J, WEMER, Johan, OOSTERHUIS, Berend, DE BOER, Anthonius, VRANCKX, Stan, DRENTH, Ben F. H, DE ZEEUW, Rokus A, DE LEIJ, Lou F. M. H, JONKMAN, Jan H. G

“…The aim of the current retrospective study was to assess the influence of polymorphic drug metabolism as assessed by genotyping, on the on the utilisation of…”
Get full text

Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge by Stangier, Joachim, Su, Chung-An P. F, van Heiningen, Pauline N. M, Meinicke, Thomas, van Lier, Jan J, de Bruin, Henrieke, Tamminga, Wim J, Jonkman, Jan H. G

“…Telmisartan is a new angiotensin receptor antagonist possessing potent, selective, and insurmountable inhibitory activity specific to the angiotensin II type 1…”
Get full text

An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19 by TAMMINGA, Wim J, WEMER, Johan, OOSTERHUIS, Berend, BRAKENHOFF, Jan P. G, GERRITS, Mireille G. F, DE ZEEUW, Rokus A, DE LEIJ, Lou F. M. H, JONKMAN, Jan H. G

“…A method for simultaneous phenotyping and genotyping for CYP2D6 and CYP2C19 was tested. Six healthy volunteers were selected (three extensive and three poor…”
Get full text

Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra‐individual reproducibility and occurrence of adverse events by Tamminga, Wim J., Wemer, Johan, Oosterhuis, Berend, Wieling, Jaap, Touw, Daan J., De Zeeuw, Rokus A., De Leij, Lou F. M. H., Jonkman, Jan H. G.

“…Aims  To further evaluate mephenytoin as a probe for CYP2C19 phenotyping. Methods  Healthy subjects (n = 2638) were phenotyped using the urinary…”
Get full text

The prevalence of CYP2C19 genotypes in a population of healthy Dutch volunteers and apparent gender differences in phenotypes by Tamminga, Wim J., Wemer, Johan, Oosterhuis, Berend, De Zeeuw, Rokus A., De Leij, Lou F. M. H., Jonkman, Jan H. G.

“…We reported the prevalence of poor metabolizers of CYP2C19 to be 1.8% in a sample of the Dutch population (n=4301; [1]). These data were obtained by…”
Get full text

Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening by WIELING, J, TAMMINGA, W. J, SAKIMAN, E. P, OOSTERHUIS, B, WEMER, J, JONKMAN, J. H. G

“…A bioanalytical method for the determination of dextromethorphan (DEX) and its metabolites dextrorphan (DTX), 3-methoxymorphinan (3MM), and 3-hydroxymorphinan…”
Get full text

Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction by Peeters, P A, Crijns, H J, Tamminga, W J, Jonkman, J H, Dickinson, J P, Necciari, J

“…The safety, and the pharmacodynamic and pharmacokinetic compatibility of clopidogrel, 75 mg daily, with the cardiac glycoside digoxin, were assessed in 12…”
Get more information

Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers: Clinical Pharmacology of Telmisartan by STANGIER, Joachim, SCHMID, Jochen, TÜRCK, Dietrich, SWITEK, Heinz, VERHAGEN, Aalt, PEETERS, Pierre A. M, VAN MARLE, Sjoerd P, TAMMINGA, Wim J, SOLLIE, Frans A. E, JONKMAN, Jan H. G

Get full text